Literature DB >> 24453711

Successful management of a neurology infusion practice.

John F Foley1, Anne M Dunne1.   

Abstract

The increasing use of infusible biologic therapies, including the novel monoclonal antibody natalizumab for the treatment of relapsing forms of multiple sclerosis, has elicited much interest among neurologists in the provision of in-office infusions for their patients. An in-office infusion center may offer neurologists a means to provide integrated care for their patients in a familiar and supportive environment. This setting is especially convenient for chronically ill patients, allowing them to receive high-quality care under the direct supervision of their neurologist and facility staff. By administering infusible treatments in a neurology practice rather than referring patients to a hospital or oncology/hematology-based infusion center, the primary neurologist can more closely monitor clinical outcomes, treatment adherence, and the occurrence of adverse effects. In addition, there is greater opportunity for patient interaction and education, which can strengthen relationships with clinical caregivers. This model is also applicable to multispecialty or hospital-based neurology groups desiring to integrate neurology infusion services. In this article, we discuss overall management strategies; staffing and scheduling issues; general coding, billing, and reimbursement methodologies; and additional financial considerations.

Entities:  

Year:  2011        PMID: 24453711      PMCID: PMC3882956          DOI: 10.7224/1537-2073-13.2.95

Source DB:  PubMed          Journal:  Int J MS Care        ISSN: 1537-2073


  21 in total

1.  Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group.

Authors:  L D Jacobs; R W Beck; J H Simon; R P Kinkel; C M Brownscheidle; T J Murray; N A Simonian; P J Slasor; A W Sandrock
Journal:  N Engl J Med       Date:  2000-09-28       Impact factor: 91.245

2.  Negotiating a contract with a health plan.

Authors:  Christine L Jones; Terry L Mills
Journal:  Fam Pract Manag       Date:  2006 Nov-Dec

3.  Going all-digital is easier said than done.

Authors:  Carrie Weimar
Journal:  Physician Exec       Date:  2009 Mar-Apr

4.  Build your own infusion clinic.

Authors:  Neil Versel
Journal:  Biotechnol Healthc       Date:  2005-02

5.  Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group.

Authors: 
Journal:  Lancet       Date:  1998-11-07       Impact factor: 79.321

Review 6.  Assessment: the use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.

Authors:  D S Goodin; B A Cohen; P O'Connor; L Kappos; J C Stevens
Journal:  Neurology       Date:  2008-09-02       Impact factor: 9.910

7.  Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.

Authors:  Richard A Rudick; William H Stuart; Peter A Calabresi; Christian Confavreux; Steven L Galetta; Ernst-Wilhelm Radue; Fred D Lublin; Bianca Weinstock-Guttman; Daniel R Wynn; Frances Lynn; Michael A Panzara; Alfred W Sandrock
Journal:  N Engl J Med       Date:  2006-03-02       Impact factor: 91.245

8.  Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

Authors:  L D Jacobs; D L Cookfair; R A Rudick; R M Herndon; J R Richert; A M Salazar; J S Fischer; D E Goodkin; C V Granger; J H Simon; J J Alam; D M Bartoszak; D N Bourdette; J Braiman; C M Brownscheidle; M E Coats; S L Cohan; D S Dougherty; R P Kinkel; M K Mass; F E Munschauer; R L Priore; P M Pullicino; B J Scherokman; R H Whitham
Journal:  Ann Neurol       Date:  1996-03       Impact factor: 10.422

9.  Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial.

Authors:  Hans-Peter Hartung; Richard Gonsette; Nikolaus König; Hubert Kwiecinski; Andreas Guseo; Sean P Morrissey; Hilmar Krapf; Thomas Zwingers
Journal:  Lancet       Date:  2002 Dec 21-28       Impact factor: 79.321

Review 10.  Monoclonal antibody treatments for multiple sclerosis.

Authors:  John W Rose; John Foley; Noel Carlson
Journal:  Curr Neurol Neurosci Rep       Date:  2008-09       Impact factor: 6.030

View more
  2 in total

1.  Patient preferences and satisfaction in a multispecialty infusion center.

Authors:  Barbara E Ostrov; Kristine Reynolds; Lisabeth V Scalzi
Journal:  Patient Prefer Adherence       Date:  2014-05-19       Impact factor: 2.711

2.  Qualitative factors shaping MS patients' experiences of infusible disease-modifying drugs: a critical incident technique analysis.

Authors:  Janni Lisander Larsen; Jakob Schäfer; Helle Hvilsted Nielsen; Peter Vestergaard Rasmussen
Journal:  BMJ Open       Date:  2020-08-20       Impact factor: 2.692

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.